Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression

Advanced Prostate Cancer Consensus Conference shared on LinkedIn:

“Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance out on European Urology.

This study evaluated long-term outcomes of prostate cancer (PCa) patients on active surveillance (AS) who had low-grade disease and no progression for at least five years. Among 774 men followed for over 10 years, the rates of upgrade to higher Gleason grades, metastasis, and mortality were assessed. By 15 years, 21% experienced an upgrade, while 61% remained free from major upgrades. PCa-specific survival was 100%, and overall survival was 95%.

Key risk factors for upgrade included older age, higher body mass index (BMI), and greater cancer volume.

The findings suggest that some stable patients could benefit from less intensive AS protocols.”

Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance

Authors: Kevin Shee, James Nie, Janet E Cowan, Lufan Wang, Samuel L Washington 3rd, Katsuto Shinohara, Hao G Nguyen, Matthew R Cooperberg, Peter R Carroll 

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn